Pfizer (NYSE:PFE) Shares Up 0.7%

Pfizer Inc. (NYSE:PFE)’s stock price shot up 0.7% during mid-day trading on Monday . The company traded as high as $26.17 and last traded at $26.05. 11,419,058 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 42,392,063 shares. The stock had previously closed at $25.86.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on PFE. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a report on Thursday, January 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Twelve research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Price Performance

The company has a 50 day moving average price of $27.23 and a 200 day moving average price of $28.79. The firm has a market cap of $145.47 billion, a PE ratio of 71.36, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the previous year, the company earned $1.14 EPS. The company’s quarterly revenue was down 41.3% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.22 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PFE. Worth Asset Management LLC acquired a new position in shares of Pfizer during the 1st quarter worth approximately $29,000. Briaud Financial Planning Inc acquired a new position in Pfizer in the 3rd quarter valued at $30,000. Main Street Group LTD acquired a new position in Pfizer in the 4th quarter valued at $30,000. GoalVest Advisory LLC raised its holdings in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the last quarter. Finally, Creekmur Asset Management LLC acquired a new position in Pfizer in the 4th quarter valued at $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.